Kailera reports 11.1% weight loss data
Compartilhar
Kailera Therapeutics (NASDAQ:KLRA) reported topline data from two Jiangsu Hengrui Pharmaceuticals Phase 3 trials of oral GLP-1 agonist HRS-7535/KAI-7535 in China, including mean weight loss of up to 11.1%.
